Suppressive effects of the antiandrogen agent, chlormadinone acetate and the 5α-reductase inhibitor, dutasteride on prostate weight and intraprostatic androgen levels in rats

Arzneimittel-Forschung/Drug Research

Volumn 61, Issue 9, 2011, Pages 515-520

  Kobayashi, Hideo ^a   Gotanda, Kotaro ^a   Shibata, Yasuhiro ^b   Watanabe, Jun Ichi ^a   Nakano, Youichi ^a   Shinbo, Atsushi ^a   Suzuki, Kazuhiro ^b  

^a Grelan Pharmaceutical Co Ltd   (Japan)

^b GUNMA UNIVERSITY   (Japan)

Author keywords

Benign prostatic hyperplasia; Chlormadinone acetate; Dihydrotestosterone; Dutasteride; Rat prostate; Testosterone

Indexed keywords

ANDROGEN; ANDROSTANOLONE; CHLORMADINONE ACETATE; DUTASTERIDE; TESTOSTERONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; MALE; NONHUMAN; ORGAN WEIGHT; PROSTATE; PROSTATE HYPERTROPHY; RAT; SEMINAL VESICLE;

EID: 80053409551     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296237     Document Type: Article

References (33)

1. Tsukamoto T, Masumori N. Epidemiology and natural history of benign prostatic hyperplasia. Int J Urol. 1997;4:233-46. (Pubitemid 127494959)
2. Roehrborn CG. Benign prostatic hyperplasia: an overview. Rev Urol. 2005;7:S3-14.
3. Kaplan SA. Current role of alpha-blockers in the treatment of benign prostatic hyperplasia. BJU Int. 2008;102(S2):3-7.
4. Lowe F. Alpha-1-adrenoceptor blockade in the treatment of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 1999;2:110-9. (Pubitemid 29438918)
5. Kanimoto Y, Okada K. Antiandrogen therapy of benign prostatic hyperplasia-review of the agents evaluation of the clinical results. Hinyokika Kiyo. 1991;37:1423-8.
6. Okada H, Kawaida N, Ogawa T, Arakawa S, Matsumoto O, Kamidono S, et al. Tamsulosin and chlormadinone for the treatment of benign prostatic hyperplasia. Scand J Urol Nephrol. 1996;30:379-85. (Pubitemid 26361739)
7. Gotanda K, Shinbo A, Nakano Y, Sasaki T, Honma S, Miyasaka K. The effect of chlormadinone acetate on the prostate of rats treated with adrenal androgens. Medical Consultation New Remedies. 1999;36:277-83.
8. Gotanda K, Shinbo A, Okada M, Nakano Y, Kobayashi H, Sasaki T, et al. Effects of combination therapy with a luteinizing hormone-releasing hormone agonist and chlormadinone acetate on rat prostate weight and plasma testosterone levels. Prostate Cancer Prostatic Dis. 2003;6:66-72. (Pubitemid 36432624)
9. Kondo Y, Homma Y, Aso Y, Kawabe K, Mieda M, Takahashi H. Relative potency of antiandrogens with reference to intracellular testosterone in the rat prostate. Prostate. 1996;29:146-52. (Pubitemid 26341819)
10. Shibata Y, Fukabori Y, Ito K, Suzuki K, Yamanaka H. Comparison of histological compositions and apoptosis in canine spontaneous benign prostatic hyperplasia treated with androgen suppressive agents chlormadinone acetate and finasteride. J Urol. 2001;165:289-93.
11. Bramson HN, Hermann D, Batchelor KW, Lee FW, James MK, Frye SV. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther. 1997;282:1496-502. (Pubitemid 27408333)
12. O'Leary MP, Roehrborn CG, Black L. Dutasteride significantly improves quality of life measures in patients with enlarged prostate. Prostate Cancer Prostatic Dis. 2008;11: 129-33. (Pubitemid 351676599)
13. Debruyne F, Barkin J, van Erps P, Reis M, Tammela TL, Roehrborn C; ARIA3001, ARIA3002 and ARIB3003 Study Investigators. Efficacy and safety of long-termtreatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol. 2004;46:488-95. (Pubitemid 39200858)
14. Roehrborn CG, Marks LS, Fenter T, Freedman S, Tuttle J, Gittleman M, et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology. 2004;63:709-15. (Pubitemid 38479415)
15. Rittmaster R, Hahn RG, Ray P, Shannon JB, Wurzel R. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer. Urology. 2008;72:808-12.
16. Wurzel R, Ray P, Major-Walker K, Shannon J, Rittmaster R. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2007;10:149-54. (Pubitemid 46881666)
17. Paris F, Servant N, Térouanne B, Sultan C. Evaluation of androgenic bioactivity in human serum by recombinant cell line: preliminary results. Mol Cell Endocrinol. 2002; 198:123-9. (Pubitemid 36169942)
18. Kemppainen JA, Langley E, Wong CI, Bobseine K, Kelce WR, Wilson EM. Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone. Mol Endocrinol. 1999;13:440-54. (Pubitemid 29113876)
19. Ozers MS, Marks BD, Gowda K, Kupcho KR, Ervin KM, De Rosier T, et al. The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wildtype androgen receptor in a time-resolved fluorescence resonance energy transfer assay. Biochemistry. 2007;46:683-95. (Pubitemid 46133586)
20. Lazier CB, Thomas LN, Douglas RC, Vessey JP, Rittmaster RS. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line. Prostate. 2004;58:130-44. (Pubitemid 38160900)
21. Shibata Y, Ito K, Suzuki, K, Nakano K, Fukabori Y, Suzuki R, et al. Changes in the endocrine environment of the human prostate transition zone with aging: Simultaneous quantitative analysis of prostatic sex steroids and comparison with human prostatic histological composition. Prostate. 2000;42:45-55. (Pubitemid 30004874)
22. Mieda M, Tarutani M, Takahashi H, Iizuka K, Nakanowatari K, Shimazawa H, et al. [The effect of chlormadinone acetate on rat prostatic atrophy.] Kiso To Rinsho. 1977;11: 158-63. Japanese.
23. Aso Y, Homma Y, Kumamoto Y, Tsukamoto T, Orikasa S, Yamanaka H et al. [Phase III study of 5 alpha-reductase inhibitor, MK-906 in patients with benign prostatic hyperplasia - A comparable double blind study with chlormadinone acetate long acting tablets]. Hinyoki Ge Ka. 1995;8:237-56. Japanese.
24. Kogawa T, Yanagiya H, Takashima T, Higashino I, Kudo T, Suzuki T, et al. Clinical evaluation of the long-term treatment with chlormadinone acetate in patients with benign prostatic hypertrophy. Hinyokika Kiyo. 1993;39:281-7. (Pubitemid 23136989)
25. Tsukamoto T, Endo Y, Narita M. Assessment of recommended dose of dutasteride on Japanese men with benign prostatic hyperplasia: a randomized, double-blind, place-bo-controlled, parallel-group, dose response study. Hinyokika Kiyo. 2009;55:209-14.
26. Tsukamoto T, Endo Y, Narita M. Efficacy and safety of dutasteride in Japanese men with benign prostatic hyperplasia. Int J Urol. 2009;16:745-50.
27. Cunha GR, Alarid ET, Turner T, Donjacour AA, Boutin EL, Foster BA. Normal and abnormal development of the male urogenital tract. Role of androgens, mesenchymal-epithelial interactions, and growth factors. J Androl. 1992;13: 465-75.
28. Ito K, Fukabori Y, Shibata Y, Suzuki K,MiedaM, Gotanda K, et al. Effects of a new steroidal aromatase inhibitor, TZA- 2237, and/or chlormadinone acetate on hormone-induced and spontaneous canine benign prostatic hyperplasia. Eur J Endocrinol. 2000;143:543-54.
29. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215-24. (Pubitemid 36859473)
30. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. REDUCE Study Group. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362:1192-202.
31. Nishiyama T, Ikarashi T, Hashimoto Y, Suzuki K, Takahashi K. Association between the dihydrotestosterone level in the prostate and prostate cancer aggressiveness using the Gleason score. J Urol. 2006;176:1387-91. (Pubitemid 44307234)
32. Moguilewsky M, Fiet J, Tournemine C, Raynaud JP. Pharmacology of an antiandrogen, anandron, used as an adjuvant therapy in the treatment of prostate cancer. J Steroid Biochem. 1986;24:139-46. (Pubitemid 16047768)
33. Mo Q, Lu SF, Simon NG. Dehydroepiandrosterone and its metabolites: differential effects on androgen receptor trafficking and transcriptional activity. J Steroid Biochem Mol Biol. 2006;99:50-8.